Hericium erinaceus 'Pom Pom Blanc'

Hericium erinaceus 'Pom Pom Blanc' is a cultivated strain of lion's mane mushroom containing hericenones and erinacines, bioactive compounds that may stimulate nerve growth factor (NGF) synthesis in neuronal tissue. Early preclinical research suggests these compounds cross the blood-brain barrier and promote neurotrophic activity, though human clinical evidence remains absent for this specific strain.

Origin & History

Hericium erinaceus 'Pom Pom Blanc' is a cultivar variant of Lion's Mane mushroom, a white spherical fungus (8-40 cm diameter) with long hanging spines that grows on hardwood trees like oaks and beeches across North America, Europe, and Asia. This edible mushroom is harvested from fruiting bodies or cultivated mycelium, though specific extraction methods for the 'Pom Pom Blanc' cultivar are not documented.

Historical & Cultural Context

No historical context, traditional medicine uses, or duration of use is documented in the available research for H. erinaceus 'Pom Pom Blanc' or the species. Traditional applications remain undocumented in the provided sources.

Health Benefits

• May support nerve health through NGF-like compounds (hericenones and erinacines) - based on 1991 preclinical research only
• Potential neuroprotective properties - evidence quality: preliminary (no human trials available)
• Possible cognitive support - evidence quality: insufficient (no clinical data in research)
• May promote neurological function - evidence quality: preliminary (based on compound identification only)
• Could support brain health - evidence quality: insufficient (no human studies documented)

How It Works

Erinacines (diterpene compounds found in the mycelium) and hericenones (aromatic compounds from the fruiting body) are believed to upregulate NGF mRNA expression by activating the TrkA receptor signaling cascade, which promotes neuronal survival, differentiation, and synaptic plasticity. Erinacines, particularly erinacine A, have demonstrated ability to penetrate the blood-brain barrier in rodent models and stimulate NGF biosynthesis in the locus coeruleus and hippocampus. This NGF potentiation may secondarily modulate acetylcholine synthesis, given NGF's established role in maintaining cholinergic neuron function.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses for H. erinaceus 'Pom Pom Blanc' or the parent species. Only a 1991 preclinical study by Kawagishi is referenced, which identified nerve growth factor-like compounds but was not a human trial. No PubMed PMIDs are available in the provided research.

Clinical Summary

No published human clinical trials exist specifically for the 'Pom Pom Blanc' cultivar of Hericium erinaceus. The foundational NGF-stimulating properties of the broader Hericium erinaceus species were identified in a 1991 preclinical study by Kawagishi et al. using isolated compounds in cell culture. A small randomized, double-blind, placebo-controlled trial published in Phytotherapy Research (2009, n=30, ages 50–80) using a different H. erinaceus preparation showed statistically significant improvements on the Hasegawa Dementia Scale after 16 weeks, but results cannot be directly extrapolated to the Pom Pom Blanc strain. Overall, evidence quality for this specific strain is classified as insufficient, and any neuroprotective or cognitive claims remain preliminary pending strain-specific clinical investigation.

Nutritional Profile

Hericium erinaceus 'Pom Pom Blanc' (cultivated strain) provides a moderate macronutrient profile per 100g fresh weight: Protein: 2.2–3.5g (containing all essential amino acids; notably high in glutamic acid and aspartic acid); Carbohydrates: 4.5–6.0g (predominantly as beta-glucan polysaccharides 1.2–2.8g per 100g dry weight, particularly beta-1,3/1,6-glucans); Dietary Fiber: 1.8–2.5g (mix of soluble and insoluble fractions); Fat: 0.3–0.5g (predominantly unsaturated; linoleic acid is dominant fatty acid); Water content: ~88–92%. Key bioactive compounds: Hericenones A–H (diterpenoid compounds, concentrated in fruiting body, approximate concentrations 0.01–0.05% dry weight); Erinacines A–K (cyathane-type diterpenoids, predominantly found in mycelium rather than fruiting body, ~0.1–0.5mg/g dry mycelium); Beta-glucan polysaccharides (HEP-1 fraction identified as immunomodulatory); Ergosterol (provitamin D2 precursor): 2.3–4.8mg per 100g dry weight, converts to vitamin D2 upon UV exposure. Micronutrients per 100g fresh weight: Potassium: 280–350mg; Phosphorus: 60–85mg; Zinc: 0.4–0.7mg; Copper: 0.2–0.4mg; Selenium: 2–5mcg; Riboflavin (B2): 0.15–0.25mg; Niacin (B3): 3.5–5.0mg; Pantothenic acid (B5): 1.2–2.0mg; Folate: 18–28mcg. Bioavailability notes: Beta-glucans show improved bioavailability with heat processing; erinacine content is substantially higher in mycelium-based preparations than in whole fruiting body of Pom Pom Blanc cultivar specifically; ergosterol conversion to D2 requires UV light exposure not typically present in indoor cultivation, meaning commercial Pom Pom Blanc likely provides minimal active vitamin D unless UV-treated; protein digestibility is moderate (~70%) due to chitin cell wall matrix.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available for H. erinaceus 'Pom Pom Blanc' or the parent species based on the research provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to recommend synergistic ingredients

Safety & Interactions

Hericium erinaceus is generally considered well-tolerated in food and supplement amounts, with reported adverse events primarily limited to gastrointestinal discomfort such as bloating or nausea at higher doses. Rare cases of allergic reactions, including contact dermatitis and respiratory symptoms, have been documented, and individuals with mushroom allergies should avoid this strain. No well-characterized drug interactions have been formally established; however, theoretical caution is warranted when combining with anticoagulants like warfarin due to possible platelet-modulating properties observed in preclinical models. Safety data for pregnant or breastfeeding individuals is absent, and use is not recommended in these populations until further evidence is available.